

Corticosteroid Treatment Selector

Charts revised January 2017. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

		ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	RAL	ABC	FTC	3TC	TDF	ZDV	E/C/F/TAF	E/C/F/TDF
Inhaled	Beclometasone	↑ ^a	↓ ^b	↑ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Budesonide	↑ ^c	↑ ^c	↑ ^c	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Fluticasone	↑ ^c	↑ ^c	↑ ^c	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Mometasone	↑ ^c	↑ ^c	↑ ^c	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Topical	Clobetasol	↑ ^{c,d}	↑ ^{c,d}	↑ ^{c,d}	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Fluocinolone	↑ ^{c,d}	↑ ^{c,d}	↑ ^{c,d}	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Hydrocortisone (topical)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Other	Betamethasone	↑ ^c	↑ ^c	↑ ^c	↓	↓	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Dexamethasone	↑ ^c ↓	↑ ^c ↓	↑ ^c ↓	↓	↓	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Hydrocortisone (oral)	↑ ^c	↑ ^c	↑ ^c	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Methylprednisolone	↑ ^c	↑ ^c	↑ ^c	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Prednisolone	↑ ^c	↑ ^c	↑ ^c	↓40%	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Prednisone	↑ ^c	↑ ^c	↑ ^c	↓40%	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Triamcinolone	↑ ^c	↑ ^c	↑ ^c	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dosage adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity (<2 fold ↑AUC or <50% ↓AUC). No *a priori* dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the corticosteroid
- ↓ Potential decreased exposure of the corticosteroid
- ↔ No significant effect

- ↑↑ Potential increased exposure of HIV drug
- ↓↓ Potential decreased exposure of HIV drug

- a Coadministration of ritonavir (100 mg twice daily) increased the concentrations of the active metabolite (beclometasone-17-monopropionate) but no significant effect on adrenal function was seen. Caution is still warranted, use the lowest possible corticosteroid dose and monitor for corticosteroid side effects.
- b DRV/r decreased the exposure of active metabolite (beclometasone-17-monopropionate) but no significant effect on adrenal function was seen.
- c Risk of elevated corticosteroid levels, Cushing's syndrome and adrenal suppression. This risk is present for oral and injected administration, and also for topical, inhaled or eye drops corticosteroids
- d The extent of percutaneous absorption is determined by many factors such as degree of inflammation and alteration of the skin, duration, frequency and surface of application, and use of occlusive dressings.

Numbers refer to increased or decreased AUC of the corticosteroid as observed in drug-drug interaction studies.